Literature DB >> 24162786

Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.

Alessandra Musso1, Silvia Catellani, Paolo Canevali, Sara Tavella, Roberta Venè, Silvia Boero, Ivana Pierri, Marco Gobbi, Annalisa Kunkl, Jean-Louis Ravetti, Maria Raffaella Zocchi, Alessandro Poggi.   

Abstract

In this study, we analyzed the influence of mesenchymal stromal cells derived from lymph nodes of non-Hodgkin's lymphomas, on effector functions and differentiation of Vdelta (δ)2 T lymphocytes. We show that: i) lymph-node mesenchymal stromal cells of non-Hodgkin's lymphoma inhibit NKG2D-mediated lymphoid cell killing, but not rituximab-induced antibody-dependent cell-mediated cytotoxicity, exerted by Vδ2 T lymphocytes; ii) pre-treatment of mesenchymal stromal cells with the aminobisphosphonates pamidronate or zoledronate can rescue lymphoma cell killing via NKG2D; iii) this is due to inhibition of transforming growth factor-β and increase in interleukin-15 production by mesenchymal stromal cells; iv) aminobisphosphonate-treated mesenchymal stromal cells drive Vδ2 T-lymphocyte differentiation into effector memory T cells, expressing the Thelper1 cytokines tumor necrosis factor-α and interferon-γ. In non-Hodgkin's lymphoma lymph nodes, Vδ2 T cells were mostly naïve; upon co-culture with autologous lymph-node mesenchymal stromal cells exposed to zoledronate, the percentage of terminal differentiated effector memory Vδ2 T lymphocytes increased. In all non-Hodgkin's lymphomas, low or undetectable transcription of Thelper1 cytokines was found. In diffused large B-cell lymphomas and in a group of follicular lymphoma, transcription of transforming growth factor β and interleukin-10 was enhanced compared to non-neoplastic lymph nodes. Thus, in non-Hodgkin lymphomas mesenchymal stromal cells interfere with Vδ2 T-lymphocyte cytolytic function and differentiation to Thelper1 and/or effector memory cells, depending on the prominent in situ cytokine milieu. Aminobisphosphonates, acting on lymph-node mesenchymal stromal cells, can push the balance towards Thelper1/effector memory and rescue the recognition and killing of lymphoma cells through NKG2D, sparing rituximab-induced antibody-dependent cell-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24162786      PMCID: PMC4007944          DOI: 10.3324/haematol.2013.097311

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  42 in total

1.  High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.

Authors:  Maria Raffaella Zocchi; Silvia Catellani; Paolo Canevali; Sara Tavella; Anna Garuti; Barbara Villaggio; Annalisa Zunino; Marco Gobbi; Giulio Fraternali-Orcioni; Annalisa Kunkl; Jean-Louis Ravetti; Silvia Boero; Alessandra Musso; Alessandro Poggi
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

2.  Harnessing γδ T cells in anticancer immunotherapy.

Authors:  Dalil Hannani; Yuting Ma; Takahiro Yamazaki; Julie Déchanet-Merville; Guido Kroemer; Laurence Zitvogel
Journal:  Trends Immunol       Date:  2012-02-23       Impact factor: 16.687

Review 3.  Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity.

Authors:  Marc Bonneville; Rebecca L O'Brien; Willi K Born
Journal:  Nat Rev Immunol       Date:  2010-06-11       Impact factor: 53.106

4.  Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.

Authors:  Hong Wang; Ghanashyam Sarikonda; Kia-Joo Puan; Yoshimasa Tanaka; Ju Feng; José-Luis Giner; Rong Cao; Jukka Mönkkönen; Eric Oldfield; Craig T Morita
Journal:  J Immunol       Date:  2011-10-19       Impact factor: 5.422

5.  ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.

Authors:  D Cosman; J Müllberg; C L Sutherland; W Chin; R Armitage; W Fanslow; M Kubin; N J Chalupny
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

6.  Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.

Authors:  V Lafont; J Liautard; J P Liautard; J Favero
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.

Authors:  H Das; L Wang; A Kamath; J F Bukowski
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

8.  Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival.

Authors:  Alessandra Musso; Maria Raffaella Zocchi; Alessandro Poggi
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

9.  Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.

Authors:  V Kunzmann; E Bauer; J Feurle; F Weissinger; H P Tony; M Wilhelm
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

Review 10.  gammadelta T cells in cancer immunotherapy: current status and future prospects.

Authors:  Shubhada Chiplunkar; Swati Dhar; Daniela Wesch; Dieter Kabelitz
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

View more
  12 in total

1.  Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

Authors:  Maria Raffaella Zocchi; Delfina Costa; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari; Simona Minghelli; Roberto Benelli; Stefano Scabini; Emanuele Romairone; Silvia Catellani; Aldo Profumo; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

2.  Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.

Authors:  Cédric Rossi; Pauline Gravelle; Emilie Decaup; Julie Bordenave; Mary Poupot; Marie Tosolini; Don-Marc Franchini; Camille Laurent; Renaud Morin; Jean-Michel Lagarde; Loïc Ysebaert; Laetitia Ligat; Christine Jean; Ariel Savina; Christian Klein; Alba Matas Céspedes; Patricia Perez-Galan; Jean-Jacques Fournié; Christine Bezombes
Journal:  Oncoimmunology       Date:  2018-12-17       Impact factor: 8.110

Review 3.  Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.

Authors:  Jabar A Faraj; Ali Jihad Hemid Al-Athari; Sharaf El Din Mohie; Iman Kareem Kadhim; Noor Muhsen Jawad; Weaam J Abbas; Abduladheem Turki Jalil
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

4.  Mesenchymal stromal cells as regulators of anti-tumour immune response.

Authors:  Alessandro Poggi; M R Zocchi
Journal:  Indian J Med Res       Date:  2015-02       Impact factor: 2.375

Review 5.  γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Front Immunol       Date:  2014-11-11       Impact factor: 7.561

Review 6.  Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment.

Authors:  Alessandro Poggi; Massimo Giuliani
Journal:  Vaccines (Basel)       Date:  2016-11-08

Review 7.  How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.

Authors:  Alessandro Poggi; Serena Varesano; Maria Raffaella Zocchi
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 8.  Tissue Adaptations of Memory and Tissue-Resident Gamma Delta T Cells.

Authors:  Camille Khairallah; Timothy H Chu; Brian S Sheridan
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

9.  ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.

Authors:  Maria Raffaella Zocchi; Caterina Camodeca; Elisa Nuti; Armando Rossello; Roberta Venè; Francesca Tosetti; Irene Dapino; Delfina Costa; Alessandra Musso; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2015-12-29       Impact factor: 8.110

10.  Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer.

Authors:  Daniele Di Mascolo; Serena Varesano; Roberto Benelli; Hilaria Mollica; Annalisa Salis; Maria Raffaella Zocchi; Paolo Decuzzi; Alessandro Poggi
Journal:  Cancers (Basel)       Date:  2019-12-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.